 Connection
Petter Bjornstad to Clinical Trials, Phase III as Topic
This is a "connection" page, showing publications Petter Bjornstad has written about Clinical Trials, Phase III as Topic.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.156 |
|
|
|
-
Pruijm M, Belmar N, Bjornstad P, Cherney DZI, Das V, Gunnarsson T, Hodgin JB, Schytz PA, Tuttle KR, Kretzler M. REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide. Kidney Int. 2026 01; 109(1):6-16.
Score: 0.057
-
Cherney DZI, Belmar N, Bjornstad P, Chacko MM, Gunnarsson TP, Hodgin JB, Kretzler M, Pruijm M, Schytz PA, Tuttle KR. Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2025 Oct 30; 40(11):2182-2192.
Score: 0.057
-
Cherney DZI, Bjornstad P, Perkins BA, Rosenstock J, Neubacher D, Marquard J, Soleymanlou N. Kidney Effects of Empagliflozin in People with Type 1 Diabetes. Clin J Am Soc Nephrol. 2021 11; 16(11):1715-1719.
Score: 0.043
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|